Skip to main content

Day: March 26, 2024

CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion

Written by Customer Service on . Posted in Public Companies.

CARBIOS-Paris Good Fashion-MemberCARBIOS becomes a member of Paris Good FashionCARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion Clermont-Ferrand, France, Tuesday 26 March 2024 (06.45am CET) CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces its membership to Paris Good Fashion, the association that unites over 100 French players in the sector – brands, designers and experts – around their commitment to sustainable fashion. CARBIOS is the first recycling technology supplier to join, demonstrating the importance given to recycling to achieve textile circularity. By contributing its revolutionary solution for the biorecycling of polyester,...

Continue reading

Prime Mining 2023 Financial and Operating Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

May 2023 Mineral Resource EstimateMay 2023 Mineral Resource EstimateVANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) — Prime Mining Corp. (“Prime”, or the “Company”) (TSV: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) is pleased to report its operating and financial results for the full year ended December 31, 2023. Prime is focused on the exploration and development of its wholly owned high-grade Los Reyes Gold-Silver Project in Sinaloa State, Mexico (“Los Reyes” or the “Project”). Prime Chief Executive Officer Scott Hicks commented, “2023 was a year of transformation for Prime, setting the stage for our 2024 drilling and technical programs, which include 40,000 metres of drilling. As we continue to explore Los Reyes and expand our technical understanding of the project, we remain dedicated to sustainable growth...

Continue reading

Leading Providers of Early Childhood Education Training Join Forces to Serve Industry Needs

Written by Customer Service on . Posted in Mergers And Acquisitions.

StraighterLine Acquires ProSolutions TrainingProSolutions TrainingProSolutions Joins StraighterLine Family of CompaniesStraighterLine and ProSolutionsTrainingStraighterLine Acquires ProSolutions TrainingWASHINGTON, D.C., March 26, 2024 (GLOBE NEWSWIRE) — StraighterLine, a creator of affordable, flexible, and career-aligned postsecondary courses, today announced the acquisition of ProSolutions Training, a professional development division of Care Solutions, Inc. that provides training for early childhood educators. This acquisition expands StraighterLine’s early childhood education training and certification solutions as ProSolutions Training (PST) joins ChildCare Education Institute (CCEI) as the newest subsidiary under StraighterLine. “Now more than ever, there is a great need for qualified early care and education...

Continue reading

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Written by Customer Service on . Posted in Public Companies.

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). “We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD,” said Mesoblast CEO Dr. Silviu Itescu. Mesoblast intends to file the resubmission during the next...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.